Last updated on December 2019

A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough

Brief description of study

This is a multi-center, randomized, double-blind, placebo-controlled, crossover, dose escalation study of BLU-5937 in subjects with unexplained or refractory chronic cough

Detailed Study Description

This study will have two 16-day treatment periods (four escalating doses or matching placebo at four days interval) separated by a 10 to 14-day washout period. There will be a 14-day follow-up period.

Clinical Study Identifier: NCT03979638

Find a site near you

Start Over

Allergy Asthma & Sinus Center

Greenfield, WI United States
  Connect »